Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Conjugate:
unconjugated
Clone:
F4, monoclonal
Application:
ELISA (i), ICC, IHC (f), IHC (p), IP, RIA, WB
Citations:
53
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
F4, monoclonal
mol wt
antigen 170-180 kDa
contains
15 mM sodium azide
species reactivity
hamster, human
technique(s)
immunocytochemistry: suitable, immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:500 using human kidney sections, immunohistochemistry (frozen sections): suitable, immunoprecipitation (IP): suitable, indirect ELISA: suitable, radioimmunoassay: suitable using cell-surface RIA, western blot: suitable
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... ABCB1(5243)
General description
The ABCB1 (ATP binding cassette subfamily B member 1) gene is mapped to human chromosome 7q21.12. It encodes for P-glycoprotein, which is a membrane bound drug transporter protein, belonging to the ATP-binding cassette (ABC) transporters family. The gene is considered to be highly polymorphic.
Immunogen
mixture of human and hamster drug-resistant whole cells and crude plasma membranes.
Application
Monoclonal Anti-P-Glycoprotein (MDR) antibody produced in mouse has been used in western blot analysis and Immunohistochemistry.
Biochem/physiol Actions
Overexpression of ABCB1 (ATP binding cassette subfamily B member 1) gene is a major cause for multi-drug resistance, which makes chemotherapy challenging for the treatment of osteosarcoma. P-glycoprotein (P-gp) mediates the energy-dependent efflux of xenobiotic to the outside of plasma membrane from the inside of the cell , thereby affecting the process of absorption, distribution, and excretion of drugs. Cyclosporine, a calcineurin inhibitor serves as a substrate for P-gp.
The antibody recognizes an epitope located in the amino terminal half of P-glycoprotein (Pgp), at the third extracellular loop of the molecule. The epitope is resistant to formalin fixation and periodate oxidation. The antibody detects specifically human MDR1 P-glycoprotein, but does not appear to recognize the human MDR3 product, nor the mouse mdr1a, mdr1b or the mdr3 P-glycoprotein.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Datasheet
T M Chu et al.
Hybridoma, 12(4), 417-429 (1993-08-01)
Using viable adriamycin resistant human ovarian carcinoma cells 2780AD and colchicine resistant human oral epidermoid carcinoma cells KB-24 as the immunogen in primary and subsequent i.p. immunizations, followed by i.v. boostings with crude plasma membranes of 2780AD, KB-24, Chinese hamster
T M Chu et al.
Biochemical and biophysical research communications, 203(1), 506-512 (1994-08-30)
Multidrug resistance (MDR) is a unique phenomenon in cancer patients and is commonly associated with an overexpression of the human MDR gene mdr1, which encodes an energy-dependent Mr 180 kDa membrane bound protein, known as P-glycoprotein. P-glycoprotein serves as a
Jingwei Ma et al.
Cell research, 26(6), 713-727 (2016-05-12)
Developing novel approaches to reverse the drug resistance of tumor-repopulating cells (TRCs) or stem cell-like cancer cells is an urgent clinical need to improve outcomes of cancer patients. Here we show an innovative approach that reverses drug resistance of TRCs